Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.67 |
| ▸ | NPC1 | O15118 | 2/20 | 0.67 |
| ▸ | RAB9A | P51151 | 1/20 | 0.67 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | CRHBP | P24387 | 2/20 | 0.60 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.60 |
| ▸ | EGFR | P00533 | 3/20 | 0.57 |
| ▸ | IGF1R | P08069 | 2/20 | 0.57 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.51 |
| ▸ | CNR2 | P34972 | 1/20 | 0.48 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.48 |
| ▸ | CLK1 | P49759 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ASPH | Q12797 | 1/20 | 0.47 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27925457 | 0.82 | POLB (0.63) | KMT2ANPC1RAB9AMEN1MAPT | |
| SCHEMBL26608015 | 0.81 | KMT2A (1.00) | KMT2ANPC1RAB9AMEN1MAPT | |
| SCHEMBL2144142 | 0.78 | KMT2A (0.65) | KMT2ANPC1RAB9AMEN1MAPT | |
| SCHEMBL8422251 | 0.78 | MEN1 (0.68) | KMT2ANPC1RAB9AMEN1MAPT | |
| SCHEMBL28131061 | 0.77 | CLK4 (0.57) | KMT2ANPC1RAB9AMEN1MAPT | |
| SCHEMBL3923979 | 0.76 | CLK4 (0.53) | KMT2ANPC1RAB9AMEN1MAPT | |
| SCHEMBL3159168 | 0.76 | CLK4 (0.56) | KMT2ANPC1RAB9AMEN1MAPT | |
| SCHEMBL1136780 | 0.76 | KMT2A (0.55) | KMT2ANPC1RAB9AMEN1MAPT | |
| SCHEMBL436482 | 0.75 | CLK4 (0.55) | CLK4DYRK1ACLK1KDM4EASPH | |
| SCHEMBL5521162 | 0.75 | MAPT (0.81) | KMT2ANPC1RAB9AMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3511333-B1 | CRYSTAL FORM AND SALT FORM OF 7H-PYRROLO[2,3-D]PYRIMIDINE COMPOUND AND PREPARATION METHOD THEREFOR | WUXI FORTUNE PHARMACEUTICAL CO LTD (CN) | 2021-05-12 | — | — | EP | disclosed |
| US-10774094-B2 | Crystal forms and salt forms of 7h-pyrrolo[2,3-d]pyrimidine compounds and preparation method thereof | Wuxi Fortune Pharmaceutical Co., Ltd (CN) | 2020-09-15 | — | — | US | disclosed |
| US-20190218231-A1 | Crystal Forms And Salt Forms Of 7h-Pyrrolo[2,3-D]Pyrimidine Compounds And Preparation Method Thereof | Wuxi Fortune Pharmaceutical Co.,Ltd (CN) | 2019-07-18 | — | — | US | disclosed |
| EP-3511333-A1 | CRYSTAL FORM AND SALT FORM OF 7H-PYRROLO[2,3-D]PYRIMIDINE COMPOUND AND PREPARATION METHOD THEREFOR | Wuxi Fortune Pharmaceutical Co., Ltd (CN) | 2019-07-17 | — | — | EP | disclosed |
| US-20180162879-A1 | JANUS KINASE INHIBITOR | Wuxi Fortune Pharmaceutical Co., Ltd (CN) | 2018-06-14 | — | — | US | disclosed |
| US-20140243334-A1 | SUBSTITUTED HYDOXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| US-8513421-B2 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| US-8513421-B2 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| US-8110687-B2 | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-02-07 | — | — | US | disclosed |
| US-8110687-B2 | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-02-07 | — | — | US | disclosed |
| US-20110288117-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-11-24 | — | — | US | disclosed |
| US-20110288117-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-11-24 | — | — | US | disclosed |
| WO-2011146591-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-11-24 | — | — | WO | disclosed |
| CN-101365682-A | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARM INC (US) | 2009-02-11 | — | — | CN | disclosed |
| EP-1957460-A1 | BICYCLIC COMPOUNDS WITH KINASE INHIBITORY ACTIVITY | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-08-20 | — | — | EP | disclosed |
| US-20070149533-A1 | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-06-28 | — | — | US | disclosed |
| US-20070149533-A1 | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-06-28 | — | — | US | disclosed |
| US-20070149533-A1 | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-06-28 | — | — | US | disclosed |
| WO-2007067444-A1 | BICYCLIC COMPOUNDS WITH KINASE INHIBITORY ACTIVITY | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-06-14 | — | — | WO | disclosed |
| WO-2007067444-A1 | BICYCLIC COMPOUNDS WITH KINASE INHIBITORY ACTIVITY | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243334-A1 | SUBSTITUTED HYDOXAMIC ACIDS AND USES THEREOF | HDAC6, H1-3, H1-5 | KMT2A 60/4885NPC1 3030/4885RAB9A 939/4885 |
| US-20110288117-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC1, HDAC5 | KMT2A 38/4885NPC1 1916/4885RAB9A 1876/4885 |
| US-10774094-B2 | Crystal forms and salt forms of 7h-pyrrolo[2,3-d]pyrimidine compounds and preparation method thereof | DPYD, TPMT, NUDT1 | KMT2A 3064/4885NPC1 3898/4885RAB9A 829/4885 |
| US-20180162879-A1 | JANUS KINASE INHIBITOR | JAK2, JAK1, JAK3 | KMT2A 1272/4885NPC1 2109/4885RAB9A 1722/4885 |
| US-20190218231-A1 | Crystal Forms And Salt Forms Of 7h-Pyrrolo[2,3-D]Pyrimidine Compounds And Preparation Method Thereof | DPYD, TPMT, NUDT1 | KMT2A 3064/4885NPC1 3898/4885RAB9A 829/4885 |
| US-20070149533-A1 | Bicyclic compounds with kinase inhibitory activity | MAP3K20, MAP3K1, MAP3K5 | KMT2A 1162/4885NPC1 1541/4885RAB9A 2160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.